Shield Therapeutics PLC IP Portfolio Update (1989Z)
13 March 2017 - 6:00PM
UK Regulatory
TIDMSTX TIDMSTXW
RNS Number : 1989Z
Shield Therapeutics PLC
13 March 2017
Shield Therapeutics plc
("Shield" or the "Group")
IP Portfolio Update
Patent estate fortified for Feraccru(R) building internationally
on the 2034 UK exclusive position
London, UK, 13 March 2017: Shield Therapeutics plc (LSE:STX), a
specialty pharmaceutical company focused on secondary care, is
pleased to announce an IP update including that IP Australia has
granted a composition of matter patent protecting the active
substance of Feraccru(R), the Company's lead product for the
treatment of iron deficiency anaemia (IDA), to late October 2035 in
Australia.
This Australian patent (Australian Patent No. 2015340825)
entitled "Crystalline Forms of Ferric Maltol", was granted
utilising an expedited examination under the Global Patent
Prosecution Highway program (GPPH) based on the UK patent (UK
Patent No. GB2531742) "Polymorphs of Ferric Maltol" granted by the
UK Intellectual Property Office (UKIPO) in September 2016
protecting the active substance of Feraccru(R) through to October
2034 in the UK.
The GPPH procedure is also being employed in the United States
and Canada and, in addition, the Company has a patent application
entitled "Crystalline Forms of Ferric Maltol" pending before the
European Patent Office (EPO) which, if granted, would protect the
active substance of Feraccru(R), Europe-wide, until October 2035.
Following International Preliminary Examination (IPE), the EPO
considered the pending claims in Europe to be both novel and
inventive.
Carl Sterritt, Founder and Chief Executive Office of Shield
Therapeutics, commented: "This grant from IP Australia has
commenced the expected expansion of territories benefitting from
the significant composition of matter IP we first attained for
Feraccru(R) from the UKIPO in September 2016. With our application
progressing well with the EPO to cover Europe and with the GPPH
procedure being utilized in the United States and Canada, we are
confident that in the coming months Feraccru(R) will benefit from
this enhanced breadth and duration of IP protection across an ever
broader range of geographies. Commercially, we are continuing to
see encouraging signals of demand from prescribers for Feraccru(R)
and we believe the Company remains in a strong position to
capitalise on this interest and deliver growth and value to our
shareholders."
Feraccru(R) received marketing authorisation across Europe in
February 2016 for the treatment of adults with Iron Deficiency
Anaemia in patients with inflammatory bowel disease. Feraccru(R) is
currently in the early stages of commercialisation in Europe,
having been launched in the UK in June 2016.
- Ends -
For further information please contact:
Shield Therapeutics plc +44 (0)20 7186 8500
Carl Sterritt, Chief Executive
Officer
Nominated Adviser and Broker
Liberum Capital Limited
Christopher Britton/Steve
Pearce +44 (0)20 3100 2222
Financial PR Advisor +44 (0)20 3709 5700
Consilium Strategic Communications shieldtherapeutics@consilium-comms.com
Mary-Jane Elliott/Matthew
Neal
About Shield Therapeutics plc
Shield Therapeutics is a specialty pharmaceutical company
focused on the commercialisation and development of late-stage,
hospital-focused pharmaceuticals which address areas of unmet
medical need. The Group has a marketed product, Feraccru(R), for
the treatment of iron deficiency anaemia (IDA) in patients with
inflammatory bowel disease (IBD) which has exclusive IP rights
until 2034. In addition, the Group is developing PT20, a late-stage
pharmaceutical for the treatment of systemic phosphate accumulation
(hyperphosphatemia). Shield Therapeutics, headquartered in London,
is listed on LSE's AIM under the ticker STX. For more information
please visit www.shieldtx.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
UPDGGUQCWUPMGQU
(END) Dow Jones Newswires
March 13, 2017 03:00 ET (07:00 GMT)
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Apr 2024 to May 2024
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From May 2023 to May 2024